# TRC105 for Recurrent Glioblastoma

> **NCT01778530** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** TRC105

## Key facts

- **NCT ID:** NCT01778530
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study was terminated due to poor accrual.
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01778530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01778530, "TRC105 for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01778530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*